
|
Report Date : |
26.04.2007 |
IDENTIFICATION
DETAILS
|
Name : |
HASSAN PHARMACEUTICAL (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
Plot # 99-A,
Industrial Estate, Jamrud Road, Peshawar |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1992 |
|
|
|
|
Com. Reg. No.: |
P-01041/19921106 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture &
Marketing of Pharmaceutical Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
Business Name
HASSAN PHARMACEUTICAL (PRIVATE) LIMITED
Full Address
|
Registered Address
& Factory |
|
Plot # 99-A,
Industrial Estate, Jamrud Road, Peshawar, Pakistan |
|
Tel |
92 (91) 5815661,
5813864 |
|
Fax |
92 (91) 5813947 |
|
|
--- |
Short Description Of
Business
|
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
Year Established |
1992 |
|
Registration # |
P-01041/19921106 |
Branches
None
Auditors
M/s Shahid Sami
& Co.
(Chartered Accountants)
1st Floor, Lumsay Arcade, Fakhar-e-Alam Road, Peshawar, Pakistan
Legal Status
Subject Company was incorporated as a Private Limited Company in 1992
|
Authorised Capital |
Rs. 10,000,000/- divided
into 100,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 3,810,000/-
divided into 38,100 shares of Rs. 100/- each |
Details of Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Muhammad Nawaz Mrs. Azra Bibi |
Pakistani Pakistani |
J-4, House # 73, Phase II, Hayatabad, Peshawar J-4, House # 73, Phase II, Hayatabad, Peshawar |
Business Business |
Chief Executive Director |
Shareholders
|
Names |
Number of Shares |
|
Mr. Muhammad Nawaz Mrs. Azra Bibi Mr. Muhammad Abbas Mr. Muhammad Kashif Mrs. Shada Bibi Mr. Pervez Akhter |
2,500 10,000 9,000 6,000 4,000 6,600 |
Associated Companies
None
Products
ACEPOL, ALUMAG PLUS, AMINOTHOL-D, ASCOTRAN, ASOQUIN, BRONCORIDE, BRONCORIDE-DM, BRONCOSAF, CE-FEROL, CO FEROL, HASVIT PLUS, HASVIT-C, PINWORM, TRIFURON-M, TRIFURON-P, ULTRA MOX, ULTRA PEN, URELEX
Number of Employees
68
Annual Production
Volume
The capacity and production of the company’s plant is indeterminable
as it is multi-product and involves varying processes of manufacture.
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2005 |
30,000,000/- (Estimated) |
Trade Suppliers
(Foreign)
CREATIVE CHEMICALS, INDIA
MAPLE BIOTECH (PVT) LIMITED, INDIA
AARTI DRUGS, INDIA.
ASHU INTERNATIONAL, INDIA.
ESKAY INTERNATIONAL, INDIA.
Customers
Mainly Pharmacies, Distributors, Hospitals & Trading Companies located in Peshawar
Bankers
MCB Bank Limited, Pakistan.
Faysal Bank Limited, Pakistan.
Bank Alfalah Limited, Pakistan.
Habib Bank Limited, Pakistan.
Foreign Exchange
Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 60.70 |
|
UK Pound |
1 |
Rs. 121.35 |
|
Euro |
1 |
Rs. 82.55 |
Comments
Subject Company was established in 1992 and is engaged in manufacture & marketing of Pharmaceutical Products. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms and conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)